First line treatment of adult men with mCRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.
Rapid Review
| Commenced | Completed | Outcome |
| 5/11/2014 | 22/12/2014 | Full Pharmacoeconomic Evaluation Recommended. |
Pharmacoeconomic Evaluation
| Commenced | Completed | Outcome |
| 09/04/2015 | 22/06/2015 | Reimbursement Not Recommended at the submitted price. |
December 2015
The HSE has approved reimbursement following confidential price negotiations.